With growing awareness of the medicinal benefits of cannabis and cannabis-derived medicinal products internationally, numerous marketing opportunities were created for which a trustworthy and competent active pharmaceutical ingredient (API) (drug substance) manufacturer is needed. This led to the establishment of MMC Laboratories in September 2022. With the knowledge and experience gained over many years in the cannabis and pharmaceutical industries by our international leadership team, we took up the task of being this trustworthy manufacturer of quality cannabis-derived APIs and based our manufacturing facility in Lilongwe, Malawi.
From its onset, MMC Laboratories (hereafter MMC) has been committed to achieving the highest possible standards regarding APIs. We obtained a cannabis licence from the Malawi Cannabis Regulatory Authority (CRA) in January 2023.
Our manufacturing facility was designed to comply with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and EudraLex Volume 4 Good Manufacturing Practice (GMP) Guidelines. We established a Pharmaceutical Quality System (PQS) following the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines that apply to API.
We have an established culture of continuous improvement at all organisational levels and constantly monitor our business’s ethical, legal, and social aspects.
MMC Laboratories manufactures bulk cannabis-derived APIs for B2B purchase. We deliver cannabis flos, CBD and cannabis terpenes for the wellness industry, highly standardised cannabis extracts and highly purified major and rare cannabinoids to our clients.